OBJECTIVE: This study aimed to investigate the impact of comorbidity on cognitive and functional decline in patients with Alzheimer dementia (AD). METHODS: One hundred and two AD outpatients examined at the Psychiatry Department of the CF2 Polyclinic in Bucharest, Romania and re-evaluated after 2 years. Comorbidity was rated using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). RESULTS: Baseline mean age (SD) was 75.4 (8.2) years, median CDR (range) was 2 (1-3), and mean MMSE (SD) 14.2 (4.9). MMSE declined to 11.2 (4.8) during follow-up. Baseline mean total CIRS-G score (SD) was 13.8 (5.4), median number of endorsed categories (range) was 8 (1-14), and mean severity index (SD) 1.9 (0.4). Main comorbidity areas were cardiovascular, ear, nose and throat, genitourinary, musculoskeletal/integument, and neurological. Severity of comorbidity increased with dementia severity (p <0.001). Baseline comorbidity was related to increased rate of cognitive decline; truncated regression coefficients (p-values) were 0.01 (0.02) for CIRS-G total score, and 0.15 (0.006) for severity index (controlled for age, sex, education, and AD treatment). Faster cognitive decline was associated with faster functional decline: OR (95% CI) was 5.2 (1.9-13.6) for increased rate of ADL change and 3.8 (1.0-14.1) for increased rate of IADL change (controlled for age, sex, education, AD medication, and comorbidity). Comorbidity tended to increase functional decline; however, the associations were not statistically significant. CONCLUSIONS: In this group of patients with AD, comorbidity increased the rate of cognitive decline. Considering comorbidity instead of focusing on separate conditions may be more helpful in managing AD.
OBJECTIVE: This study aimed to investigate the impact of comorbidity on cognitive and functional decline in patients with Alzheimer dementia (AD). METHODS: One hundred and two AD outpatients examined at the Psychiatry Department of the CF2 Polyclinic in Bucharest, Romania and re-evaluated after 2 years. Comorbidity was rated using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). RESULTS: Baseline mean age (SD) was 75.4 (8.2) years, median CDR (range) was 2 (1-3), and mean MMSE (SD) 14.2 (4.9). MMSE declined to 11.2 (4.8) during follow-up. Baseline mean total CIRS-G score (SD) was 13.8 (5.4), median number of endorsed categories (range) was 8 (1-14), and mean severity index (SD) 1.9 (0.4). Main comorbidity areas were cardiovascular, ear, nose and throat, genitourinary, musculoskeletal/integument, and neurological. Severity of comorbidity increased with dementia severity (p <0.001). Baseline comorbidity was related to increased rate of cognitive decline; truncated regression coefficients (p-values) were 0.01 (0.02) for CIRS-G total score, and 0.15 (0.006) for severity index (controlled for age, sex, education, and AD treatment). Faster cognitive decline was associated with faster functional decline: OR (95% CI) was 5.2 (1.9-13.6) for increased rate of ADL change and 3.8 (1.0-14.1) for increased rate of IADL change (controlled for age, sex, education, AD medication, and comorbidity). Comorbidity tended to increase functional decline; however, the associations were not statistically significant. CONCLUSIONS: In this group of patients with AD, comorbidity increased the rate of cognitive decline. Considering comorbidity instead of focusing on separate conditions may be more helpful in managing AD.
Authors: Maria Vassilaki; Jeremiah A Aakre; Ruth H Cha; Walter K Kremers; Jennifer L St Sauver; Michelle M Mielke; Yonas E Geda; Mary M Machulda; David S Knopman; Ronald C Petersen; Rosebud O Roberts Journal: J Am Geriatr Soc Date: 2015-08-27 Impact factor: 5.562
Authors: Marcello Tonelli; Natasha Wiebe; Sharon Straus; Martin Fortin; Bruce Guthrie; Matthew T James; Scott W Klarenbach; Helen Tam-Tham; Richard Lewanczuk; Braden J Manns; Hude Quan; Paul E Ronksley; Peter Sargious; Brenda Hemmelgarn Journal: CMAJ Open Date: 2017-08-14
Authors: Priya Palta; A Richey Sharrett; Jennifer A Deal; Kelly R Evenson; Kelley Pettee Gabriel; Aaron R Folsom; Alden L Gross; B Gwen Windham; David Knopman; Thomas H Mosley; Gerardo Heiss Journal: Alzheimers Dement Date: 2018-10-12 Impact factor: 21.566
Authors: Maria Vassilaki; Jeremiah A Aakre; Walter K Kremers; Michelle M Mielke; Yonas E Geda; Rabe E Alhurani; Taru Dutt; Mary M Machulda; David S Knopman; Prashanthi Vemuri; Preciosa M Coloma; Barbara Schauble; Val J Lowe; Clifford R Jack; Ronald C Petersen; Rosebud O Roberts Journal: J Gerontol A Biol Sci Med Sci Date: 2019-05-16 Impact factor: 6.053
Authors: Elisa Fabbri; Yang An; Marco Zoli; Toshiko Tanaka; Eleanor M Simonsick; Melissa H Kitner-Triolo; Stephanie A Studenski; Susan M Resnick; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2016-04-30 Impact factor: 5.562
Authors: Kan Z Gianattasio; Erin E Bennett; Jingkai Wei; Megha L Mehrotra; Thomas Mosley; Rebecca F Gottesman; Dean F Wong; Elizabeth A Stuart; Michael E Griswold; David Couper; M Maria Glymour; Melinda C Power Journal: Alzheimers Dement Date: 2021-02-01 Impact factor: 16.655